Abstract Number: 1435 • ACR Convergence 2022
Effectiveness of Combination Therapy with Tocilizumab and Low-Dose Prednisolone as an Induction Therapy in Biologics-Naïve Patients with Rheumatoid Arthritis: A Prospective, Randomized, Controlled, Open-Label, Multicenter Study
Background/Purpose: Efficacy and safety of tocilizumab (TCZ) in the treatment of rheumatoid arthritis (RA) has demonstrated in randomized controlled trials. However, the clinical response to…Abstract Number: 1834 • ACR Convergence 2022
Canakinumab Treatment in Familial Mediterranean Fever Patients with Colchicine Resistance: A Single-center Study
Background/Purpose: Recurrent fever and serositis are the hallmarks of Familial Mediterranean fever (FMF). Colchicine is known for yielding high success in disease control by obviating…Abstract Number: 2112 • ACR Convergence 2022
Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Background/Purpose: Guselkumab (GUS) is associated with robust and sustained improvement in PsA signs and symptoms in subgroups of patients (pts) pooled from the phase 3…Abstract Number: 2200 • ACR Convergence 2022
Reliability of Medication Information Derived from EHR Data Compared to Insurance Claims: An Analysis of Biologic Medications in RISE and Medicare
Background/Purpose: Health services studies increasingly rely on Electronic Health Record (EHR) data to capture medication use. However, the reliability of medication information derived from EHR…Abstract Number: 0138 • ACR Convergence 2022
Patients with Familial Mediterranean Fever (FMF) Under Canakinumab Treatment – Long-term Efficacy and Safety Interim Data of the RELIANCE Registry
Background/Purpose: Familial Mediterranean fever (FMF) is a chronic disease characterized by recurrent episodes of fever and serositis, with a risk of severe complications (e. g.…Abstract Number: 0313 • ACR Convergence 2022
Olokizumab Improves Patient Reported Outcomes in Moderate to Severely Active Rheumatoid Arthritis Patients Inadequately Controlled by Methotrexate (MTX-IR): Results from the Phase III Randomized Controlled Trial
Background/Purpose: Olokizumab (OKZ) is an interleukin-6-inhibitor for treatment of Rheumatoid Arthritis (RA). In these analyses, we present patient reported outcomes (PROs) reported by MTX-IR patients…Abstract Number: 0423 • ACR Convergence 2022
Direct and Indirect Effect of TNFi on BASMI Components in People with Axial Spondyloarthritis: A Longitudinal Study
Background/Purpose: The Bath Ankylosing Spondylitis Metrology Index (BASMI) is an index of spinal mobility for people with axial spondyloarthritis (axSpA). BASMI is one of the…Abstract Number: 0759 • ACR Convergence 2022
Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRD) on Immunomodulatory Therapies (IMT): An Updated Cohort Study
Background/Purpose: AIIRD patients may have a blunted immune response to the COVID-19 vaccines, but this is uncertain as these individuals were not included in clinical…Abstract Number: 0850 • ACR Convergence 2022
Outcomes of Patients with Juvenile Idiopathic Arthritis Following Failure of Initial Tumor Necrosis Factor Inhibitor Medication in the Childhood Arthritis and Rheumatology Research Alliance Registry
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are the most commonly used first biologics to treat juvenile idiopathic arthritis (JIA), but it is unknown what subsequent…Abstract Number: 1015 • ACR Convergence 2022
Predictors of Nail Response with Guselkumab: A Post Hoc Analysis of the VOYAGE 2 Clinical Trial
Background/Purpose: Understanding factors that impact response to therapy may help improve disease management, clinical outcomes and patient quality of life. Nails are often overlooked in…Abstract Number: 1289 • ACR Convergence 2022
Evaluating Peri–operative Preferences of Bariatric Surgeons in the Management of Immunosuppressive Therapy During Bariatric Surgery
Background/Purpose: As the number of bariatric procedures increases, surgeons will encounter more patients on long-term immunosuppressive medications that may increase post-operative complications. Currently, there are…Abstract Number: 1438 • ACR Convergence 2022
The Ratio Between Biological and Glucocorticoid Use in Different Countries Worldwide: Results from the METEOR Registry
Background/Purpose: Previous studies have demonstrated differing bDMARD prescription rates between countries, which seems to be amongst others related to a country's socioeconomic status. In contrast,…Abstract Number: 1842 • ACR Convergence 2022
Vaccination in Patients with Autoinflammatory Periodic Syndromes Under Canakinumab – Safety Data Interim Analysis of the RELIANCE Registry
Background/Purpose: Treatment of autoinflammatory periodic syndromes with the interleukin-1β inhibitor canakinumab (CAN) has been shown to be safe and effective in clinical trials and in…Abstract Number: 2113 • ACR Convergence 2022
Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies
Background/Purpose: Despite available PsA treatments, a portion of PsA patients (pts) does not achieve improvements in PsA signs and symptoms according to ACR response criteria.…Abstract Number: 2209 • ACR Convergence 2022
Efficacy of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis Subtypes of Juvenile Idiopathic Arthritis: Results from a Randomized, Phase 3 Study
Background/Purpose: Juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) represent pediatric counterparts of adult non-radiographic axial spondyloarthritis and psoriatic…
- « Previous Page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- …
- 54
- Next Page »